Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, whether he has made an assessment of the sustainability of prosthetics and orthotics apprenticeship provision in England; and what steps she is taking to support its continuation.
Answered by Andrew Western - Parliamentary Under-Secretary (Department for Work and Pensions)
The department works closely with the Department for Health and Social Care to support the availability of a diverse range of training routes into health and care careers. We have worked with the health and care sector to design the Level 6 prosthetics and orthotics and Level 6 therapeutic radiography standards. These are approved for delivery and information about these standards, including funding bands, is published here and here.
Apprenticeship providers are independent bodies responsible for making their own decisions about which courses they deliver.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, whether he has made an assessment of the adequacy of therapeutic radiography apprenticeship provision; and what steps she is taking to support the long-term viability of those courses.
Answered by Andrew Western - Parliamentary Under-Secretary (Department for Work and Pensions)
The department works closely with the Department for Health and Social Care to support the availability of a diverse range of training routes into health and care careers. We have worked with the health and care sector to design the Level 6 prosthetics and orthotics and Level 6 therapeutic radiography standards. These are approved for delivery and information about these standards, including funding bands, is published here and here.
Apprenticeship providers are independent bodies responsible for making their own decisions about which courses they deliver.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of (a) trends in the level of variation in access to NICE-recommended biologic medicines for severe asthma.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made. NHS England is working with the health innovation networks and has formed the Respiratory Transformation Partnership. Focusing on improving the outcomes of people living with asthma and chronic obstructive pulmonary disease (COPD), this programme seeks to find scalable ways to decrease premature mortality and bed occupancy from respiratory diseases. Initiatives will seek to improve disease recognition, optimise delivery of National Institute for Health and Care Excellence (NICE) approved approaches at neighbourhood level, and uptake of existing and emerging biologic therapies.
The current NHS England severe asthma service specification is being revised by the Specialised Respiratory Clinical Reference Group. The current service specification is available at the following link:
The revised specification will support the management of patients who require further investigation and treatments including biological medicines. The specification will also be updated to reference the most recent clinical guidelines such as the British Thoracic Society, NICE, and the Scottish Intercollegiate Guidelines Network asthma guideline covering diagnosing, monitoring, and managing asthma in adults, young people, and children, and which is expected to improve outcomes for people with asthma and identify early those who require further investigation and treatments including biologic medicines. This guideline is available at the following link:
https://www.nice.org.uk/guidance/ng245
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent engagement his Department has had with the devolved Administrations in relation to the recommendations of The Hughes Report, published on 7 February 2024; and whether any Ministerial-level discussions are planned with the governments of Scotland, Wales and Northern Ireland.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
While health is predominantly devolved, the Department holds some reserved functions and working together across the United Kingdom on health and social care is ingrained in the values of our National Health Service and social care sector.
The Patient Safety Commissioner’s report covered England-only, however, any response by the Government to the recommendations of the Hughes Report in England will likely have implications for the devolved administrations and their constituents. Engagement between officials across the UK occurs regularly and during an Inter-Ministerial Group meeting on 11 December 2025, the Hughes report was discussed and ministers across the four nations agreed to meet in January 2026 for further engagement.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the planned timeline is for publishing the next iteration of the taxonomy being developed as part of the ongoing reforms to Drug Tariff Part IX.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The final draft, version 1.2, of the Part IX Drug Tariff (Med Tech in the community) Wave 1 categorisation was developed in collaboration with an Expert Reference Group and updated in line with stakeholder feedback over four iterations. The final version was published in October 2025 and can be found on the NHS Business Services Authority Website at the following link:
https://www.nhsbsa.nhs.uk/manufacturers-and-suppliers/drug-tariff-part-ix-information
The Department is currently recruiting Independent Assessment Panels (IAPs) for Wave 1 and has agreed to ask them to review late feedback received from a company on the eye drops category. This is due to take place in February 2026 and will not require further input from industry as it has already been circulated for comment by them.
The Department has also offered to review Drug Tariff Committee feedback regarding the categorisation of medical devices that fall into waves 2 to 4.
The categorisation for waves 2 and 3 is currently being reviewed, and the Department expects to share the updated versions in early 2026 well in advance of the projected launch of waves 2 and 3 in 2027 and 2028 respectively. There are no confirmed plans for reviewing wave 4 at this time. The earliest launch would be in January 2029. All dates are subject to the outcome of the review of wave one.
The Department recognises that the categorisation is not stagnant and may need further amendments as medical devices continue to evolve and the IAPs are stood up. Companies can suggest further amendments when they apply to Part IX of the Drug Tariff or through the Drug Tariff Committee.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 October to Question 77603 on Brain: Tumours, what steps he plans to take to incentivise pharmaceutical companies involved in developing vaccines for brain tumours to approach the NHS Cancer Vaccine Launch Pad for funding and support.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the financial year 2024/25, the NIHR’s reported spend on cancer research was over £141.6 million through its research programmes and infrastructure, reflecting cancer’s high priority.
The Government is taking measures to boost research into brain tumours. In December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million with significant further funding due to be awarded in 2026.
We also support the Rare Cancers Private Members Bill. This bill aims to incentivise research and investment into treatment by introducing measures to streamline clinical trial recruitment, allow patients to be more easily contacted by researchers, and also mandates a review of orphan drug regulations.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain tumours. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
Asked by: Ben Goldsborough (Labour - South Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to (a) alter and (b) mitigate the National Institute for Care and Excellence's downgrading of terminal cancer to moderately severe.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not classified terminal cancer as moderately severe. The NICE is an independent body and is responsible for developing the methods and processes it uses to evaluate whether new medicines should be recommended for routine National Health Service funding.
In developing recommendations on whether medicines represent a clinically and cost effective use of NHS resources, NICE is able to apply a weighting that recognises the additional value that society places on treatments for severe conditions. The weighting that is applied is calculated for each appraisal based on information on the expected shortfall in life expectancy and quality of life of people with the condition taking into account existing treatment options. NICE has concluded for several appraisals of medicines for advanced cancer that a weighting should be applied based on the severity of the condition. The latest data for appraisals published up to September 2025, show that NICE has recommended 84.8% of treatments for advanced cancers since the severity modifier was introduced compared to 69.1% under its previous methods.
NICE is monitoring the impact of the changes made following the methods review and has committed to considering modular updates to its methods and processes in the future. NICE has also commissioned research to gather further evidence on societal preferences that will inform future methods reviews.
Asked by: Cameron Thomas (Liberal Democrat - Tewkesbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 1 December 2025 to Question 93580 on Eating Disorders: Mental Health Services, which external stakeholders his Department is engaging with in the development of the modern service framework for mental health.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government plans to publish the modern service framework for severe mental illness in the latter half of 2026.
Engagement on the modern service framework will involve a wide range of stakeholders, such as people with lived experience, clinicians, allied professionals, social workers, the voluntary, community and social enterprise sector, commissioners, and National Health Service Leaders. We have recruited a third Co-Chair for the Modern Service Framework, Jo Lomani, who is a national mental health co-production lead and expert by lived and living experience, to support the implementation of our lived-experience involvement and co-production strategy. This aims to ensure that people who use mental health services stay at the centre of everything we do.
Asked by: Jess Asato (Labour - Lowestoft)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the introduction of digital and AI tools in mental health care enhances rather than replaces the work of qualified counsellors and psychotherapists, in line with guidance from professional bodies such as the National Counselling and Psychotherapy Society.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
To deliver the shift from analogue to digital that is set out in the 10-Year Health Plan, we will create a digital front door for mental health care through the NHS App to boost access to early support and empower people to take steps to manage their symptoms.
Digital and artificial intelligence (AI) tools in mental health care can enhance and complement the work of qualified counsellors and psychotherapists, not replace human-delivered care. These tools can help with routine tasks like managing appointments, answering basic queries, updating clinical notes, and booking sessions. This means that clinicians can spend more time providing care to patients and patients have an improved experience across the care pathway, for example through reduced waiting times. Any new tools are introduced within a comprehensive regulatory framework in the National Health Service, underpinned by rigorous standards for safety, effectiveness, ethics, and data protection.
Publicly available AI applications that are not deployed by the NHS, such as ChatGPT and Character.AI, are not regulated as medical technologies and may offer incorrect or harmful information. Users are strongly advised to be careful when using these technologies.
Asked by: Ben Coleman (Labour - Chelsea and Fulham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of healthcare provision in prisons for inmates with diabetes; and what steps he is taking to ensure that diabetic prisoners have timely access to appropriate medical treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England commissions prison health care services into every prison in England. Every prison has onsite health care services including, primary care, mental health, dentistry, and substance misuse teams. This includes the care and management of those with long term conditions such as diabetes. All prisons offer a range of appointments to meet the needs of patients, and this includes routine appointments and urgent appointments.
NHS England commissions health care in prison that is the equivalence of community health care. The National Service Specification for primary care defines what this means for patients who require support. Access to health provision is available to every person in prison at any stage of their sentence, and this begins at the point of entry. NHS England also commissions health needs assessments across prisons to determine the needs and requirements of the prison population.
NHS England is reviewing the National Primary Care Service Specification to ensure it continues to meet the needs of the prison population.